Experience with International Neuroblastoma Staging System and Pathology Classification

Area of Science:

• Pediatric Oncology
• Cancer Staging and Classification
• Neuroblastoma Research

Background:

• The International Neuroblastoma Staging System (INSS) and International Neuroblastoma Pathology Classification (INPC) were established to standardize neuroblastoma diagnosis and prognosis.
• However, their clinical utility and impact on survival outcomes in contemporary patient cohorts require further investigation.

Purpose of the Study:

• To evaluate the clinical value of the INSS and INPC in predicting survival outcomes for neuroblastoma patients.
• To assess the association of biological factors with prognosis in different age groups.

Main Methods:

• Analysis of 644 neuroblastoma patients treated between 1995 and 1999.
• Stratification of patients by age (<12 months and >=12 months).
• Evaluation of survival rates based on INSS stages, INPC histology, and biological factors (MYCN amplification, DNA diploidy, 1p deletions).

Main Results:

• Both INSS stage and INPC histology were significantly associated with 4-year overall survival in both age groups (P<0.0001).
• Patients with INSS stage 4 or unfavorable histology had significantly lower survival rates.
• MYCN amplification and DNA diploidy were identified as independent prognostic factors.

Conclusions:

• The INSS and INPC are crucial for predicting neuroblastoma patient survival, independent of other factors.
• Age, INSS stage, and INPC histology are key determinants of treatment outcomes.
• Biological markers like MYCN amplification further refine prognostic assessments.